Voluntis develops digital therapeutics using its Theraxium technology platform. The company is focused on tools to support patients treated for cancer and is exploring applications in neurology. Voluntis and Eisai will collaborate to design and develop innovative digital therapeutics for oncology patients using Theraxium. Eisai made a strategic investment in Voluntis as part of the collaboration. The partners plan to explore additional opportunities to develop, evaluate and commercialize Theraxium-based digital therapeutics in neurology. The article presents this activity as part of Voluntis expanding its global pharma collaborations. Voluntis develops proprietary companion software dedicated to managing chronic conditions, with a focus on diabetes, anticoagulation and hemophilia. Its Voluntis Insulin Therapy Manager (VITM) is designed to support patients across the insulin pathway. The company also provides partners with development and regulatory capabilities to build digital solutions on its core system architecture. Voluntis plans to use the new funding to accelerate development of its diabetes management solution, advance programs in other chronic diseases, and ramp up US operations. The company has offices in Paris and Boston and was founded in 2001 by CEO Pierre Leurent. The Series D proceeds will support product development and geographic expansion in the US.

Total raised

$29M

Funding rounds

2

Latest round

Series D

Latest activity

Apr 2014